https://www.facebook.com/groups/longstrawtips/
Printable View
cheers KW, I always appreciate your thoughts. Quarterly will reveal more.
I have a small holding in Circadian Technologies which is up 52% over the past month, with the majority of its shares being owned by funds outside Australia. Plenty of cash and comparison with other opthamology companies with 10-60 times mcap makes interesting reading (p17 - http://www.circadian.com.au/sites/de...%2007%2009.pdf )
AVH First patient treated in US military Wound trial
Cogstate - hitting 40c today, I'm up 30% in the last couple of weeks since buying. Looking like a breakout even though volumes light. Only regret is not buying more.
Hi , Anyone in or been in Compumedics ? (CMP.ax)
There is a recent research report on their investor page
http://www.compumedics.com.au/index....tors-relations
No position currently, but taking a look .
Here keep up will you:mellow::)
Download DocumentAVH appoints ReCell distributors
Download Document AVH extends Recell IP Patent
Download Document CEO invited to present
Download Document Quarterly
Ann: Avita Medical Reports 63% Decreased Length of Hospital Stay
Only 12 patients but very promising.S/P drops ?
Earlier this fall, the U.S. Food and Drug Administration (FDA) approved an expansion of Avita’sCompassionate Use Investigational Device Exemption (IDE) program for ReCellŪ. As part of the expansion,the FDA doubled the patient number to a total of 24 patients who have insufficient healthy skin availablefor standard skin grafting of their injury.
Download Document
FDA'S Grant Avitas Recell Expedited Access Pathway
Cogstate CGS starting to get recognised, good research by a guy who is a deep value investor. Now around 50c, with valuations between 60c-$1. Last announcement stated we are likely to get further contracts.
Up another 30% over the past 2 months. While still under the radar in Australia, there was a substantial buy from Union Investment's Luxembourg subsidiary yesterday.
According to Wikipedia: In March 2013 Union Investment became the first investment association to be awarded five stars eleven times in a row in the investment funds guide of the German business magazine Capital.[7]
Make of that what you will :)
Happy new year. Hope 2015 was a great investing year for you too. I'm late to the party with this one. Wish I'd noticed your great tip a few months ago NZSilver - risk-reward profile was fantastic at those prices. Still looks interesting but am struggling to confidently do 'inductive' ballpark calculations of likely cashflows over the next year and beyond based on company data. Could you or Percy help me out there?
Checkout the research here...
http://www.capitalhmanagement.com.au/research/
Thanks noodles ; i have signed up an read the research which is good to my unprofessional eye. Very conservative valn of 53c. Est fair valn range 63 to 78c fully diluted
"Strong rev and contract growth"
"Rapidly Growing mkt"
"Mkt leading tech"
"Operating leverage and earnings growth"
"Sticky customers"
"Aligned board and management"
"Attractive valn"
"Blue sky opps"
Def worth reading whole article
Brilliant site thank you
Keep an eye on http://shareidea.com.au/ as well. More small cap research
Indeed they are in early trials and unprofitable, albeit apparently sitting on $18m cash. They used to be a kind of biotech incubator with fingers in several pies. Over past year they've ditched other divisions and put sole focus on treatment for Wet AMD, the leading cause of blindness in the western world, with a potential market of $5 billion in the US and $10b worldwide. Hence the recent 'rebranding' to Opthea.
According to their reports, current treatments are ineffective for at least half of patients short-term and the vast majority in the long-term. They only target "VEGF-A" while Opthea's 'OPT-302' molecule targets VEGF-C and VEGF-D and could therefore be used in conjunction with current treatments to enhance outcomes. The science is a million miles over my head but from a business point of view I do like the chances of selling a potential complementary product, rather than competing head on with the incumbents in the sector.
I suppose becoming a pure-play in such a potentially lucrative market has gained investor attention.
Obviously a highly speculative stock which will become worthless if trials are unsuccessful. I have a small holding. Would be interested in other members' thoughts.
Up 26% today :)
More healthcare than strictly biotech but here's a recent report from Morgans on the Aust health sector.
https://dpsi7pmz5b6vt.cloudfront.net...eid=9f402457b0
Thanks macduff int stuff in the bigger end of town.
AVH announcement ReCell distributor appointed Germany Austria and Switzerland
Download Document
Have started a thread on MDC(forgot about this one)
Medlab Clinical Limited (MDC) is a biological research facility, specialising in the development of novel therapeutics from bacteria Medlab's focus on bacteria based medicines, which Section 4 contribute to improved gut health in key health areas, provides significant commercial potential in unmet health needs
JT...you have turned into a bit of a micro cap fiend :D:D:D. I enjoy reading the posts and analysis, as well as those of others contributing to this often neglected area of investing (NZSilver, DarkHorse, etc). Please keep them coming.
Cheers
Trigger
Thanks trigger; just passing on info better researchers than i have passed to me :mellow:DYOR
Have a look at what PAA have been doing lately.
Still working my way through the "A"s!
;)
Haven't checked right back.Is anyone in VLA Viralytics VLA?.Cancer, melanoma etc. Heres a few research reports Roth have a $3.84 target ,s/p 79c atm. A couple of friends hold.
Eye-Catching MITCI Data
Viralytics’ Cavatak Delivers Benefits In Combination With Checkpoint Inhibitors
CAVATAK Plugging Away on All Fronts; Nice CALM and MITCI Updates
MITCI Results Show Promise
I've been in for about a year - taking a small position on the first leg up from memory and adding a few more in the SPP. It was very much a punt though since I'm not familiar with the field and have recently re-balanced. That aside, they have a solid cash position, the recent news results/news flow seems to have been well-received and you have to love the price targets floating round
.
http://www.asx.com.au/asx/research/company.do#!/OPT
OPT - OPTHEA: Positive news today from first human trial, jumped 10% :)
Good one.New one on me OPT and at a 1 year high.Missed your post DH.
I have done nothing for a while.The stocks i traded are a in the dumps last i looked so glad i left in the black.Only holding NRT deep in the red and getting a bit stale on it. Sa la vie. Glad some can still mine the biotech successfully. Anyone else doing well on anything in what isa depressed sector as i see it ,generally.?
Cheers JT. Like several health related stocks - hold PGC and LHC, and seriously looking at SDI - see http://www.capitalhmanagement.com.au...07/26/sdi-ltd/
But only hold OPT in biotech - c'est tout :)
Here's an interesting take on Australian life sciences stocks.
http://www.ndfresearch.com/the-comin...-sciences.html
Thanks macduffy. A coming boom in life sciences (Bio?)stocks ; i hope so. the thing is whats the easiest way to pick the sector taking off. I hope to start a thread about identifying and sharing a sector that takes off like the M/S did recently for great gains if one picked up on it early.
Two great announcements by NRT today. Im still deep in the red atm. but this looks redeeming; thinking longer term as one needs to with BIO's .DYOR
Dr James Garner presentation to Rodman & Renshaw conference-NRT.AX
FDA approves IND application for Cantrixil-NRT.AX
Does anyone else hold OPTHEA? Up a further 18% today, with latest trial results well received by "retina professionals".
http://www.marketwired.com/press-rel...xy-2157305.htm
The share price has risen steadily to have quadrupled in 12 months :)
Beautifully simple business model - unique but complementary therapy for the leading cause of blindness - ie not competing with existing drugs but enhancing their effectiveness.
Another one thats slipped through my widespread out fingers (sigh). Very int sector and subject. My father was, and possibly me , in the macular degeneration zone so its of personal interest. Has it 4 bagged for you DH?
Thanks for your response JT. Nice to think this company may help you and millions of others. Yes has 4 bagged for me :) Still has potential upside, and with test results lower downside risk.
Nice report here on Innate Immunotherapeutics (currently testing a treatment for MS), a spec buy with a relatively low risk thanks to a heap of positive non-trial results. Something like 80% of the current Phase IIb trial patients have requested ongoing treatment beyond the end of the trial which is a very positive indicator of the drug's efficacy. Results due next year. Have held this for a couple of years.
http://www.innateimmuno.com//irm/com...storsTakeToIIL
Its been a while folks. In fact i forgot about this thread. Only holding NRT atm as I'm in concrete with this.Will persevere a while ,until a hammer drill materializes ( i accept fault:).So forgot all about OPT which has been a stellar performer along with these and 2017 top 6 picks(what a performance in 2016.
http://www.innateimmuno.com/irm/comp...opSixPicks2017
should add CYP to the biotech list, surprised it's not listed in there
pretty hot little stem cell company, been rising steadily last few months
still low market cap, but has made great progress in 2016 and huge potential
dyor, etc
Biotech set to regain favour? Mainly covers the bigger biotech stocks - FPH gets a mention.
http://www.theage.com.au/business/bi...04-gtm71i.html
Interesting article thanks. Good to see both Wilsons and Bell Potter share my positive view on Opthea :)
Have bought BOT since my last post and have just seen they too are on the marijuana thing . Anything that mentions cannabis is multi bagging atm (see marijuana thread). Didn't buy BOT for a flakey; crazy, short lived dangerous trade like that but i guess its abonus if the s/p does get a boost. BOT have many other trials and things in progress so its not like a short one horse race. S/P hasn't gone ballistic since announcement below.Not a recco DYOR
Today Botanix Pharmaceuticals released a new company update presentation, available for viewing on the ASX here. The presentation outlines Botanix’s compelling investment case and strategy.
Investment Highlights:
• Experienced US based leadership team in place with a proven track record of achieving FDA approvals
• Addressing growing, multi-billion dollar dermatology markets with no new products approved in last 20 years (within the acne space)
• Key products based on pharmaceutical grade synthetic cannabidiol (versus variable naturally derived cannabidiol), greatly enhances the probability of clinical development success
• Exclusive global rights to use PermetrexTM delivery technology for all drugs that treat skin diseases with potential to deliver near term revenues
• Accelerated development pathway for dermatology pharmaceuticals compared to standard development pathways, driving lower costs and a faster timeline to approval
• Strong intellectual property portfolio which includes 12 patent applications across 6 patent families, and substantial volumes of proprietary knowledge, know-how, and trade secrets
• Multiple near term potential revenue streams to complement longer term development upside
Matthew Callahan, Executive Director, commented, “Recent enhancements to Botanix’s senior leadership, expansion of the PermetrexTM license and new patent applications ensures Botanix is well positioned to capitalise on early value creation opportunities. Our focus now is on the rapid commercialisation of our lead acne product and developing our wider portfolio of medical dermatology products.”
BOT holding up extremely well atm with re 23% dilution ;cap raise to Instos at 5.5c.S/P has dropped only to 6.6c atm. Maybe I'm a bit early with my enthusiasm and those Instos will sell down; but so far a very strong endorsement of all the products BOT has.
OPT (see post 140 above) up 34% today on positive trial results and successful cap raise - biggest one day rise I've enjoyed for a long time, can't resist sharing it :t_up:
We few celebrate with you:t_up:. Im going to spend time looking back through the threads at opps in Bio and small cap disruptive and cannabis stocks next few days.Some gems in there.
Thanks JT! Look forward to seeing what you unearth in the next few days :)
A stock i have been watching for a while is AVH, their device has had amazing results for burn victims, like with all these types of companies a lot of hurdles still to go through and might be bit too soon to buy in as not commercial yet, but funded with 61.9m to get them through with inventory.
Massive potential, and the IP rights help protect the downside of any competition, and i haven't come across any real direct rival as yet.
Not holding, yet...
Nice to see independent director Michael Sistenich, with strong biotech management AND investment banking credentials, buying another 200K of Opthea stock at 93 cents :)
Bought in Oct 2015(see above threads) sold in May 2016. have lost track, it was/is a liz fave.
Absolute Pearler of an update , qtly on MEB today.Hold but in the red atm.
Quarterly ASX Update and Cashflow
ITD, been in for about a month up 25%, still very undervalued. Probably deserves its own thread. On a forward PE of approx 13, sales of blood collection unit/bag taking off. Will run up to $1+ in the next year, Enjoy
Sorry haven't found the time or motivation for this guys.
Meanwhile BOT announcement here, i still hold DYOR.
ASX/Media Release 8 May 2017
"Botanix commences first clinical study for BTX 1503
Brisbane Australia, 8 May 2017: Medical dermatology company Botanix Pharmaceuticals Limited (“Botanix” or “The Company”) today announced the commencement of a Phase 1a study for its lead acne treatment product BTX 1503.
BTX 1503 is a new topical treatment for moderate to severe acne, which utilizes synthetic cannabidiol as the drug active, together with Botanix’s proprietary PermetrexTM drug delivery technology. The Phase 1a study will be conducted over the coming weeks, with data from the study expected to be available by the end of June 2017.
“This first study is designed to provide safety, dosing and pharmacokinetic data for BTX 1503”, said Botanix Executive Director Matt Callahan, “these data will support the rapid advancement of BTX 1503 into our pilot acne patient trial, which will follow soon after study completion.”
BTX 1503 is targeting the market for prescription acne market products that currently generates more than $4.5 billion in annual sales. Supporting scientific data suggests that BTX 1503 may inhibit the excessive production of oil in the skin, which is a primary cause of acne, as well as potentially reducing inflammation and bacterial infection.
“We are very pleased to achieve this milestone within 9 months of initiating the BTX 1503 program,” Mr Callahan commented.
“This study will also form the basis for our planned dermatitis program, which we expect to accelerate into the clinic later this year following our recent successful capital raising.”
Acne is the most common skin disorder in the US affecting 40-50 million Americans. Acne has multiple pathogenic pathways including overproduction of oils, inflammation and bacterial infection. Currently the only product approved that has an effect on oil production also carries significant side effects, including birth defects, lymphoma and suicide risks. BTX 1503 is expected to have a far superior side effect profile, based on the published clinical data for cannabidiol in other disease indications.
About Botanix Pharmaceuticals
Botanix Pharmaceuticals is dedicated to developing next generation therapeutics for the treatment of serious skin diseases. Our mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. Botanix is harnessing the untapped potential of a synthetic active pharmaceutical ingredient known as cannabidiol, which has a well-established safety profile. Botanix is preparing for the first human trials with synthetic cannabidiol utilising a proprietary drug delivery system (PermetrexTM) for direct skin
delivery of the therapy in 1H 2017 and plans to progress the development of its pipeline of other PermetrexTM enabled products alone, or in collaboration with partners."
More director buying in OPT - 48K and 109K shares
BOT( spekky DYOR)
Botanix Pharmaceuticals was recently covered by a range of analysts and research notes which highlighted the company’s key investment drivers as well as the unique proposition the company offers to investors.
Banyan Tree Investment Group produced an in-depth research note which detailed how the company’s leading acne product, BTX1503, could unlock significant value and that Botanix
“remains attractively priced in absolute terms relative to its ASX-listed cannabis and pharmaceuticals peers”. Click here to read the full report.
Botanix was also featured in the April edition of The Passionate Investor and Under The Radar. Both reported on the company’s activities and the use of synthetic cannabidiol as the novel drug active, which is preferred by regulators for its pharmaceutical grade quality and purity. Click here for the issue of The Passionate Investor (please refer to page 21) and here for the Under the Radar Report.
Lastly, earlier in March, Argonaut also initiated coverage of Botanix which highlighted that BTX1503 has “the potential to be a ‘game-changing’ treatment for moderate to severe acne”. Click here for the full report.
Botanix also recently conducted a video interview with its Executive Director Matt Callahan where he discussed the company’s commencement of Phase 1a study for BTX1503 and upcoming milestones. Click here to view the video.
For more information about Botanix, please subscribe to the company’s investor updates by emailing achan[@]buchanwe.com.au.
Note: Botanix does not endorse, confirm, or express a view as to the accuracy of, the forecasts or other statements contained in the materials cited above. Botanix should not be taken to make any representation about its future performance by citing those materials
PAA looks interesting - seem to have turned the corner with positive earnings and new CEO after years of delays which have sapped interest...still tiny mcap. Any thoughts - is anyone following?
Will hopefully get alook at it thanks.
Ive posted on MEB somewhere before. Anyway i hold ,and good announcement out confirming 80% accurate in diagnosing PTSD post traumatic stress disorder PDF
"Over 22 army vets committed suicide a day due to PTSD or depression ,mental disorder."
Thanks for bringing MEB to our attention JT, looks very interesting. I found a useful research report: https://www.baillieuholst.com.au/pub...EB_27jun17.pdf
Financials obviously pretty speculative but interesting analysis of the opportunity - particularly comparison of their objective test with alternative screening methods for mental illness.
BOT kicking goals. If one invest s in biotech ones mindset needs oodles of patience
Botanix Completes Successful Phase 1 BTX 1503 Clinical Study
Successful Pilot Study for BTX 1701 Facial Cleanser
VHT don't think I've mentioned this one , been in a while s/p been going down but today whammo up 26% today
Volpara Health Technologies Limited (VHT) develops digital health solutions to enable personalised, high - quality breast cancer screening based on objective measurements of breast density, compression and radiation dose.
Investor Presentation - FY2017 Results Im still in the red.DYOR
Cheers DH, heres some more. Michael Phelps olympic champion is onboard now too.
https://www.statnews.com/2017/07/21/...nosis-medibio/
https://www.medgadget.com/2017/07/e...ers-interview-jack-cosentino-ceo-medibio.html
CYP - Cynata Therapeutics is looking good at this price level. Feels like it might be ready for some upside.
Few recent independent research reports published with significantly higher share price targets. Potentially significant phase 1 clinical trial news expected towards end of year...
http://cynata.com/category/news/
DYOR
Have been looking at MEB - yet to jump in but obviously depression is a huge area, and with double the diagnostic accuracy of other methods and - so they say - no competitors at present - it certainly looks interesting.
I'd be interested to know what others think (esp contrary views). Here's the script of Alan Kohler's interview with the CEO:
https://hotcopper.com.au/threads/ann...2#.WXcON9J95a0
Moving on up. Reckons they will move from 1-3 % of USA breast screening mkt.
Investor Newsletter
Now in trading halt re ethics approval for its acne patient study.
Research note out below too.
Argonaut Snapshot - Clearing Regulatory Hurdles
Sadly depression and suicide on the rise. MEB is well placed to help here.
Medibio Investment Presentation Update
https://youtu.be/hcr7IO_0Sug
Joshuatree
You maybe interested in MDR, MedAdvisor, an app linking in GP's, pharmacies, patients to streamline the script renewal process and allow patients access to manage there own information. Spoke to my GP bout it, but as its Australian, not in use here. NZ has Share Care for Hospitals, After hours and GP's to access certain details.
Can see how this will take off, saves time, money and provides a service I'd personally benefit from.
Thanks; yes its on my watchlist but with over 400 its easily lost in the mix. Cashflow positive 2018 maybe and strong comp from Health Engine and Chemist Warehouse by the looks. Up to 830,000 active users and growing.Be good to be onboard when /if a tipping point gets reached.
VHT
The five-year contract will see both of Imaging Associates’ breast centres benefit from improved image consistency and quality, as well as more accurate radiation dosage, breast compression and personalised breast density assessment for every patient.
So thats why s/p up 27%:)
"Handling 2,500 breast imaging patients annually, this is the first Victorian site to adopt VolparaEnterprise software, and the ninth clinic in Australia to be using a Volpara product."
https://www.biospace.com/News/volpa...l-with-melbourne-based/470987/source=MoreNews
ITD (ITL on ASX) research may be of int
Download
MEB decent agreement with global co Otsuka
BOT
Download Document 108.76KB
"Acne is the most common skin disorder in the US affecting 40-50 million Americans and more than250 million patients worldwide each year. "
- “FDA is very supportive of our approach to conduct well-controlled and regulated clinical studies todemonstrate the safety and efficacy of BTX 1503, and we are excited about the potential for BTX1503 to be one of the first new prescription products to treat acne approved by FDA, in more than20 years.”
VHT
Appendix 4C - quarterly On track for 200+% ARR
Highlights:
- Cash position NZ$9.29m
- Q2 FY18 Total Contract Value (TCV) NZ$2.32m, up 339% from NZ$528k in Q2
FY17- Annual Recurring Revenue (ARR) NZ$2.14m at the end of Q2 FY18, up 94%
from NZ$1.1m at the end of FY17- 25 SaaS customers signed to VolparaEnterpriseTM software, including
significant US “luminary sites”
VHT clearance in Taiwan Download Document 280.42KB
Sold half my BOT today in current meltup. Hope there is a good reason for it.
Has anyone looked at Polynovo, PNV, lately? Shareprice climbing steadily on encouraging news.
Disc: Not holding but interested.
More positive news and price action for CYP lately
15 Jan 2018 price was 58c
Current price today at 28 March 2018 is around $1.45
market cap still potentially small at $130m
no revenues yet etc, but tech looking very promising
MEB the mental health check app is now available and companies are using it, as diverse as Rio Tinto and the AFL rugby league.
Download Document 152.6KB
VHT great stuff s/p strong after 60c spp. 83.5c atm close to a new high. Sales ramping up big time.
2018 FINANCIAL RESULTS AND CAPITAL RAISE UPDATE
Highlights:
- Total revenue from contracts with customers up 53%
- Revenue from VolparaEnterprise customers up 1,945%
- Cash receipts from customers exceeded NZ$3m for the first time
- Gross margin has increased to 70%, up from 63% in FY17
- Net loss after tax improved 8%, reducing from NZ$9.6m in FY17 to NZ$8.8m in FY18
- Completion of a successful A$20 million capital raise
Wellington, NZ, 29th May 2018: Volpara Health Technologies (“Volpara”; ASX: VHT), a medical technology company whose AI imaging algorithms assist the early detection of breast cancer, has today released its full-year results for the financial year ended 31 March 2018.
The company has delivered strong year-on-year growth as a result of the successful transition, only begun in FY17, from a predominantly capital sales model to a Software as a Service (SaaS) model, as illustrated in the table below:
]SaaS revenue
Capital revenue
Service maintenance agreements revenue Other revenue
Total revenue
Total income, incl. grants
Gross margin percentage (%)
Net loss after taxes (NZ$’000’s)
Cash receipts from customers (NZ$’000’s)Total no. of VolparaEnterprise contracts signed Market share (No. & % of US women) (‘000’s) Annual Recurring Revenue (ARR) (NZ$’000’s) Total Contract Value (TCV) (NZ$’000’s)
FY18NZ$’000
1,902 575 304 31
2,812
3,535
70 (8,818) 3,068 57 1,297 (3.2%) 3,571 11,200
FY17NZ$’000
93 1,527 219 -1,839 2,047
63 (9,571) 2,270 14 294 (0.7%) 1,104 4,100
$ VarianceNZ$’000
1,809 (952) 85 31
973
1,488
7 753 798 43 1,003 2,467 7,100
% Variance
+1,945% -62% +39% +100%
+53%
+73%
+11% -8% +35% +307% +341% +223% +173%
]]Volpara CEO Dr Ralph Highnam said of the results: “These results reflect the tremendous progressthat has been made in FY18, where we met all our objectives, including increasing ARR by more than 200%, while keeping costs mostly in line with FY17 and increasing our market share to more than 3% of US women. It is pleasing to see our progress now beginning to be reflected in the financial results we are delivering.”
Cash on hand was NZ$4.84m as at 31 March 2018, and now is approx. NZ$24.5m after the successful placement and share purchase plan which has since raised A$20m for the Company.
“We have continued to develop VolparaEnterprise throughout FY18 while also making tremendous advances in our product pipeline, with some exciting new products set to be released to the market towards the end of the calendar year,” Dr Highnam said. “These products will help to ensure we have happy customers and at the same time draw more customers in and increase price per woman. With the successful capital raise, we now have the funds necessary to continue our strong growth, but as always we are still very much focused on preserving and improving shareholder value with prudent spending.”
No comment to make there DH.Am looking to take profits at some point, this has turned into a long trade partly due to my belief and partly to my lack of discipline(should have sold way back for a smaller gain and moved on) and yes competition will come or is already there.
Then again sold BOT too early and missed the stellar rise. sa la vie
Fair enough...same story with some of my smaller holdings...c'est la vie?
VHT Volpara , kiwi digital health firm on the ASX. Targeting $9 million sales in the next year. (i hold)
Volpara Health Technologies exceeds revenue goal - Scoop NZ
https://youtu.be/-xc4nsy2FJ8
Download Document 6.68MB
VHT another big tick for this NZ company
VHT at a new high up 15% today.Am staying with this trend!
Screening 3.2% of USA women atp.
https://youtu.be/TWx3hlCi8r0
VHT up another 11% today
https://www.livewiremarkets.com/wire...cks-in-october
VHT complete bounce back today on more good developments
Download Document 145.29KB
New Zealand Breast Screening First to Utilize Volpara AI Software to Improve Mammography Quality
Volpara is in multiple large-scale trials with public screening programs across Europe and APAC of its Enterprise software, including the PROCAS II project with the NationalHealth Service in the UK, one of the world’s largest screening programs. BreastScreen Central is the first such organization in the world to purchase the VolparaEnterprise software to use as a key component of its quality assurance protocols, monitoring breast compression, positioning and other factors to improve the consistency of mammographic imaging and patient experience.
VHT Excellent result in whats normally a slow time of year. Reoccurring rev and take-up adoption getting better and better , lots of global growth ahead imo.
Appendix 4C - quarterly
OPTHEA: latest edition of Bioshares highlights excellent trial results to date (vision improvements) and potential for patient investors to be "very well rewarded" - see summary in today's HC post
Thanks heres the detail to make it interesting
Ticker OPT
Opthea CEO Presentation of Trial Updates at OIS@AAO 2018
VHT, new high today on no news ,just plenty of belief that this will be a global local.